Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced additional significant findings of TurboCBD(TM), the company’s proprietary, DehydraTECH(TM) powered, cannabidiol (”CBD”) fortified hemp-oil capsule upon completion of further data analyses from its 2018 randomized, placebo-controlled, double-blinded European human clinical study. According to the update, a single 90mg dose of TurboCBD as compared to the same dose of generic CBD provided evidence of lower blood pressure, higher blood flow to the brain, faster delivery onset and larger quantities of CBD into the bloodstream. The study revealed key metabolic and hemodynamic performance findings linked to bioavailability enhancements. “The findings that Lexaria’s DehydraTECH(TM) technology can enable superior cannabinoid delivery are unique in this healthy-human clinical trial. However, the findings that the technology can proffer a positive influence on blood pressure and perfusion to the brain are truly remarkable,” Principal Investigator and Co-Director of the Centre for Heart, Lung and Vascular Health, UBC Okanagan Campus, Kelowna, Canada Professor Philip Ainslie, Ph.D. stated in the news release. “The potential benefits of this approach, but over the acute and more chronic time periods, in more middle-aged or elderly populations should now be prioritized. Establishing the impact of CBD delivery on the health of the circulatory systems, including the brain, could have major implications for the adjunct treatment of high blood pressure and some neurological diseases.”
To view the full press release, visit http://ibn.fm/cJ6ce
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs),nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
